Search Results - samir khleif

HOME SEARCH RSS
1 Results Sort By:
PD1+CD38+ CD8 T-cells, a marker for anti-PD1 therapy resistance and selection marker for treatment or continuation of treatment of patients, and a target to reverse resistance
PD1+CD38+ CD8 T-cells, a marker for anti-PD1 therapy resistance and selection marker for treatment or continuation of treatment of patients, and a target to reverse resistance Current state of the art A number of new checkpoint inhibitors are used in cancer therapy. PD-1 inhibitors such as Pembrolizumab (Keytruda), Nivolumab (Opdivo), and Cemi...
Published: 5/21/2019   |   Inventor(s): Samir Khleif, Vivek Verma, Seema Gupta
Keywords(s):  
Category(s): Therapeutics
© 2019. All Rights Reserved. Powered by Inteum